12:00 AM
 | 
Sep 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Arbaclofen placarbil: Development discontinued

XenoPort discontinued development of XP19986 to treat acute back spasms after preliminary data from a double-blind, U.S. Phase II trial in 151 patients showed that the compound missed all secondary efficacy endpoints, including a significant...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >